KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue: 2010-2021

Historic Current Deferred Revenue for Emergent BioSolutions (EBS) over the last 12 years, with Dec 2021 value amounting to $16.4 million.

  • Emergent BioSolutions' Current Deferred Revenue fell 85.90% to $15.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $15.9 million, marking a year-over-year decrease of 85.90%. This contributed to the annual value of $16.4 million for FY2021, which is 83.62% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Current Deferred Revenue of $16.4 million as of FY2021, which was down 83.62% from $100.1 million recorded in FY2020.
  • In the past 5 years, Emergent BioSolutions' Current Deferred Revenue registered a high of $100.1 million during FY2020, and its lowest value of $16.4 million during FY2021.
  • Over the past 3 years, Emergent BioSolutions' median Current Deferred Revenue value was $88.9 million (recorded in 2019), while the average stood at $68.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Current Deferred Revenue skyrocketed by 333.48% in 2017, and later slumped by 83.62% in 2021.
  • Emergent BioSolutions' Current Deferred Revenue (Yearly) stood at $30.5 million in 2017, then soared by 139.67% to $73.1 million in 2018, then grew by 21.61% to $88.9 million in 2019, then climbed by 12.60% to $100.1 million in 2020, then tumbled by 83.62% to $16.4 million in 2021.